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Introduction
Acquired immunodeficiency syndrome (AIDS) is caused by the human immunodeficiency virus (HIV), which ultimately destroys the immune system. The major targets of HIV infection are the CD4 + T lymphocytes and monocytes/macrophages. Rendering these cells resistant to HIV replication via gene therapy should result in significant reduction, if not complete elimination, of HIV in infected individuals. The therapeutic gene may express RNAs (ie antisense RNAs, sense RNAs and ribozymes) and/or proteins (ie receptors, trans-dominant mutants, single-chain antibodies and RNases) that interfere with the virus life cycle. [1] [2] [3] Therapeutic benefit may be obtained if the interfering RNA/protein molecules inhibit HIV replication for a sustained period of time and the inhibition is not overcome by a mutation(s) within the HIV genome. Also the therapeutic gene, if acquired by HIV via recombination, should not confer any advantage to the virus.
With the exception of ribozyme-and RNase-based strategies, most existing gene therapy strategies require stoichiometric binding of interfering molecules to HIV RNA/protein molecules. Consequently, an excess of the interfering molecules is required to shift the equilibrium towards the bound form. Furthermore, since the HIV RNA/protein is not consumed in the reaction, a slight shift in the equilibrium may be sufficient to permit HIV replication to proceed beyond the inhibitory step, allowing virus to replicate. On the other hand, ribozymeand RNase-based strategies may be preferred since both of these molecules cleave HIV RNA resulting in a permanent loss of RNA function and act in a catalytic manner thus requiring low concentrations to be effective. Ribozyme activity in vivo requires that the nucleotides within the HIV RNA target site(s) be conserved. Mutations outside the target site can also affect ribozyme activity by creating secondary structures, which may sterically hinder target site accessibility to the ribozyme. Given the high mutagenic rate of HIV, the emergence of HIV escape mutants is thus highly probable. In contrast, there is little latitude for the emergence of HIV escape mutants in RNase-based strategies where cleavage is not dependent on a conserved target sequence.
RNases may be designed to: (1) confer selective toxicity to HIV-infected cells; (2) cleave RNA present within virus particles yielding non-infectious progeny virus; or (3) cleave HIV RNA within the cell inhibiting progeny virus production. The first approach may be accomplished by HIV trans-activator of transcription (Tat)-and/or regulator of expression of virion proteins (Rev)-inducible expression 4 ,5 of a 'cytotoxic RNase'. [6] [7] [8] [9] Strategies based on the second approach have been designed by using fusion proteins containing the HIV-1 virion protein R (Vpr) or HIV-2 virion protein X (Vpx) domain and the bacterial Staphylococcal nuclease (SN) domain. 10 The fusion proteins were shown to be packaged into progeny virus; however, they were susceptible to HIV protease cleavage. 10 Use of HIV protease-resistant 'packageable RNases' or co-administration of HIV protease inhibitors may be required for this strategy to work. The third approach requires selective degradation of HIV RNA within the infected cell without causing cytotoxicity. Most existing RNases cleave single-stranded RNAs at a specific ribonucleotide or double-stranded RNAs at any ribonucleotide, 11 but do not posses target RNA specificity. A 'targeted RNase' may be designed by fusing a ribonucleo-lytic domain and an HIV RNA binding domain, derived from a cellular 12, 13 or viral 14, 15 protein, such that the RNase will acquire HIV RNA specificity. A targeted RNase, Tat-RNase H, containing the HIV-1 Tat and HIV-1 RNase H domains was previously designed and shown in our laboratory specifically to cleave an RNA containing the HIV-1 trans-activation responsive element (TAR) in vitro. 16 However, this RNase failed to inhibit HIV-1 replication in a lymphoid cell line (our unpublished results). The fusion protein may have been ineffective in vivo since HIV-1 RNase H cleaves RNA/RNA hybrids with a low catalytic efficiency 17 and may have specific ion requirements. 18 To improve the targeted RNase strategy further, TevRNase T1 was designed to contain HIV-1 Tev 19 and Aspergillus oryzae RNase T1 domains. 20 The HIV-1 Tev protein contains 201 amino acids. 21 This protein is produced early in the virus life cycle from a multiply spliced RNA, 19, 22 which contains the first coding exon of tat, a small portion of the env and the second coding exon of rev. Therefore, Tev contains both TAR and Rev response element (RRE) binding domains. TAR is present at the 5′ and 3′ ends of all HIV RNAs, while RRE is present on unspliced and partially spliced HIV RNAs only. The Tat-TAR interaction enhances transcription from the HIV promoter, 23 whereas the Rev-RRE interaction is required for stability, nuclear export and translation of singly spliced and unspliced HIV RNAs. [24] [25] [26] Tev can replace Tat function, while contradictory results have been obtained for Rev function. 21 RNase T1 is made of 104 amino acids 27 with a cleft containing both RNA binding and catalytic activities. RNase T1 specifically recognizes and cleaves the guanylate residues within the single-stranded RNA such that cleavage produces mono-or oligoribonucleotides with terminal 3′ phosphates. 28 In this paper, the tevT1 gene encoding the targeted RNase, Tev-RNase T1, was designed and cloned into a retroviral vector. Expression of active Tev-RNase T1 and its lack of toxicity were demonstrated in a transduced CD4 + human T lymphoid (MT4) cell line. The ability of Tev-RNase T1 to delay HIV-1 replication and its potential mode of inhibition were demonstrated in both transduced MT4 cells and human peripheral blood lymphocytes (PBLs). This study demonstrates the feasibility of a targeted RNase strategy for therapeutic use.
Results
Tev-RNase T1 design and rationale The tevT1 gene was designed to produce a 304 amino acid fusion protein, Tev-RNase T1, containing amino acids 1 to 201 of HIV-1 Tev and amino acids 2 to 104 of A. oryzae RNase T1 (Figure 1 ). The Tev domain was used so that both TAR and RRE within HIV RNA would be recognized for cleavage. The RNase T1 domain was used since it is catalytically efficient (k cat , 81 s Pools of G418-resistant stable MT4 transductants were selected and further tested. 
HIV-1 (NL4-3 strain) susceptibility of MoTN (-᭜-) and MoTN-TevT1 (--᭹-) transduced MT4 cells. Infections were performed using (a) 30 ng (p24 equivalent) of HIV-1 for 2 h or (b) 100 ng (p24 equivalent) of HIV-1 for 6 h. The amount of HIV-1 p24 antigen present in the infected cell culture supernatants is shown at various time intervals.

Figure 6 PCR and RT-PCR analysis of HIV-1-infected MT4 transductants to determine the mode of inhibition of Tev-RNase T1. Samples were analyzed from the HIV-1 challenge experiment shown in Figure 5b. (a) PCR analysis to detect the presence of HIV-1 provirus DNA synthesized following infection. On day 6 after HIV-1 infection, genomic DNA from MoTN (lane 2) or MoTN-TevT1 (lane 3) transduced MT4 cells was analyzed by PCR using Vpr-5′ and Vpu-3′ primers specifically to amplify a 424 bp region within the HIV-1 proviral DNA. A control PCR using no DNA was also performed (lane 1). (b) RT-PCR analysis to detect the presence of HIV-1 RNA following infection. On day 6 after HIV-1 infection, total RNA from MoTN (lane 2) or MoTN-TevT1 (lane 3) transduced MT4 cells was analyzed by RT-PCR using Vpr-5′ and Vpu-3′ primers to amplify a 424 bp region specific to HIV-1 RNA. A control RT-PCR using no RNA was also performed (lane 1).
cells were selected for 4 days. The pools of PBL transductants lacking or expressing Tev-RNase T1 were then challenged with 1.5 ng (p24 equivalent) of a clinical isolate of HIV-1. The amount of HIV-1 p24 antigen released in the cell culture supernatants was measured over time. To confirm inhibition after integration, the HIV-1 provirus DNA levels in the two cell types were analyzed by a semi-quantitative PCR method. Under these conditions, a linear relationship exists between the amount of DNA used and the intensity of the PCR product (Figure 9, lanes  5-13) . Semi-quantitative PCR analysis of genomic DNA 
(c) RT-PCR analysis to detect the presence of HIV-1 RNA following infection. On day 3 after HIV-1 infection, total RNA from MoTN (lane 2) or MoTN-TevT1 (lane 3) transduced PBLs was analyzed by RT-PCR using Gag-5′ and Gag-3′ primers. A control RT-PCR using no RNA was also performed (lane 1).
The above results demonstrate the efficacy of TevRNase T1 in delaying HIV-1 replication in human PBLs and also substantiate that Tev-RNase T1 acts after integration by reducing the level of HIV-1 transcripts.
Discussion
An RNase may be used in antiviral therapy for destruction of infected cells, [6] [7] [8] [9] for inactivation of virion RNA, 10 or for inactivation of viral RNA within the infected cells. 16, 37 For HIV gene therapy, the first approach may be developed by providing cells susceptible to infection with a 'cytotoxic RNase' which would, upon induction by a viral regulatory protein, 4, 5 cause selective death of cells that do become infected by HIV. The second approach requires that cells be provided with a 'packageable RNase' so that virion RNA is inactivated. This approach involves interference in the late phase of the virus life cycle such that the progeny virus produced from the genetically modified cells is non-infectious. Although this strategy is aimed at inhibiting subsequent rounds of infection, the genetically modified cells that become infected may be susceptible to a cell-mediated immune response or rendered non-functional with regards to immune function because production of viral proteins is still maintained. Since gene therapy for HIV is aimed at reconstituting an HIV-resistant immune system, the genetically modified cells must not only inhibit virus replication but also maintain normal cell functions. Although the two strategies can potentially inhibit virus replication, they also confer negative selection to the genetically modified cells. Therefore, their efficacy may depend on genetic modification of all cells in the immune system so that upon elimination of infected cells and in the absence of new infections, uninfected cells will repopulate the immune system. In contrast, the third approach requires that cells be provided with a 'targeted RNase' for viral RNA inactivation within the cell. Conse- 1 and 2) . In parallel, Gap-5′ and Gap-3′ primers were used to amplify a 122 bp region within the endogenous GAPDH gene (lanes 3 and 4) quently, selective destruction of viral RNA will be achieved early in the virus life cycle without destroying the cell and potentially allowing maintenance of normal cell functions. Those cells expressing the targeted RNase would inhibit viral replication, maintain viability and eventually out-compete the cells susceptible to infection. By natural selection, the immune system could thus be reconstituted with a population of resistant and functional cells.
We present here data supporting the feasibility of a targeted RNase approach in HIV gene therapy. The targeted RNase, Tev-RNase T1, was shown to be enzymatically functional. Intracellular expression of Tev-RNase T1 in MT4 cells and human PBLs resulted in a significant delay of a laboratory strain and a clinical isolate of HIV-1, respectively. Tev-RNase T1 was shown to interfere with the HIV-1 life cycle after integration. Also, cells expressing Tev-RNase T1 were viable and showed no signs of toxicity.
In order to understand the mode of interference of TevRNase T1, MT4 transductants were infected at a higher viral dose and the HIV-1 provirus DNA and HIV-1 RNA content in the cells was monitored over a 6-day period. The enzymatic function of Tev-RNase T1, as shown in vitro, suggests that Tev-RNase T1 can cleave substrate RNA non-specifically. However, lack of toxicity despite active protein production suggests that intracellularly Tev-RNase T1 does not cleave non-specifically. TevRNase T1 specificity in vivo is expected to be dependent on the initial binding event of HIV-1 Tev to TAR or RRE within HIV RNA and the proximity of the catalytic domain to guanylate residues. The initial binding event by the Tev domain is expected to occur with up to a 10 4 -fold higher affinity than the RNase T1 domain. Therefore, Tev-RNase T1 is expected to cleave HIV-1 RNA at available guanylate residues within and outside the TAR and RRE regions. Bacteria, higher plants and mammals utilize several RNases for host defense. These RNases are cytotoxic since they appear to reach the cytosol of cells by a receptor-mediated pathway where they can readily degrade cellular RNA. 38 HIV-1 Tev contains a nuclear localization signal and is mainly localized within the nucleus. 21 Therefore, Tev-RNase T1 is predicted to cleave HIV-1 RNA primarily within the nucleus. The absence of cytotoxicity suggests that nuclear host RNA is not available for cleavage by Tev-RNase T1. The emerging view of nuclear structure involves the existence of compartments of heterogeneous RNA-protein complexes involved in RNA metabolism like splicing, transport, polyadenylation and stabilization. 39 Therefore, the compartmentalization of nuclear bodies within the nucleus during RNA metabolism may prevent any association of nuclear host RNA-protein complexes with Tev-RNase T1. Host nuclear RNA exclusion in combination with the specific affinity and compartmentalization of Tev-RNase T1 with HIV RNA may thus be important factors contributing to the efficacy of Tev-RNase T1 with regards to viral inhibition and lack of toxicity in the cell.
An effective targeted RNase strategy is expected to depend on both the cleavage efficiency and specificity. For HIV gene therapy, the cleavage efficiency and speci-ficity could be further improved by using an RNase with separable RNA binding and catalytic domains. 40 A fusion protein containing Tev and only the catalytic domain of such an RNase should allow cleavage that would solely depend on the specificity of target RNA-binding by the RNA-binding motif of Tev. The use of targeted RNases in HIV gene therapy also raises the issue of potential immunogenicity. Targeted RNases containing TAR-or RRE-binding domains 12, 13 and an RNase domain of human origin may alleviate this problem. 11 This study demonstrates for the first time the feasibility of a targeted RNase approach for human gene therapy. Strategies are being developed to improve on the design of this and other RNases to increase their anti-HIV potential further. In addition, fusion constructs using targeted DNases, lipases and proteases may invite other opportunities for selective degradation of HIV provirus DNA, the virion lipid bilayer and viral proteins, respectively.
Materials and methods
Vector constructions
The tevT1 gene was constructed by a two-step PCR as described previously 16 using Pfu DNA polymerase (Stratagene, La Jolla, CA, USA). The RNase T1 gene was amplified by PCR using the pA2T1 27 template and the TevT1 junction-5′ (5′-AGT-CAG-GAG-CTA-AAG-AAG-CTT-GCG-ACT-ACA-CTT-3′) and T1-3′ (5′-CTA-AAG-ATC-TCT-ATG-TAC-ATT-CAA-CGA-AGT-3′) primers. This PCR product, containing the RNase T1 coding region, and the Tev-5′ primer (5′-GTC-TGC-AGC-ATA-TGA-TGG-AGC-CAG-TAG-ATC-C-3′) were used in a second PCR to amplify the tev gene from the pTev plasmid. 21 The resulting 943 bp PCR product contained an NdeI restriction site, the tevT1 coding region, and a BglII restriction site. This DNA was digested with NdeI and BglII and cloned at the NdeI and BamHI sites within the E. coli expression vector, pET-15b (Novagen, Madison, WI, USA). The resulting vector was referred to as pET-TevT1. The tevT1 gene and the SV40 promoter were then subcloned in a retroviral vector, MoTN, 41 as follows: twostep PCR was performed to amplify a cassette containing the SV40 promoter driving tevT1 gene expression. In the first PCR, TevT1-5′ (5′-GAT-ATC-GAA-TTC-ACC-ATG-GAG-CCA-GTA-GAT-CC-3′) and TevT1-3′ (5′-GCG-CAT-CGA-TCT-ATG-TAC-ATT-CAA-CGA-AGT-3′) primers were used to amplify the tevT1 gene from the pETTevT1 plasmid. This PCR product and the SV-5′ primer (5′-CGG-AAG-ATC-TAA-TAC-GAC-TCA-CTA-T-3′) were then used in a second PCR, using the pB1-SVR68 42 template, to amplify the SV40 promoter upstream of the tevT1 coding region. The resulting PCR product contained a BglII restriction site, the SV40 promoter, the tevT1 gene and a ClaI restriction site. This cassette was digested with BglII and ClaI and cloned at the BamHI and ClaI sites within the MoTN vector. The correct clone was referred to as MoTN-TevT1.
Transduction of MT4 cells and PBLs
Amphotropic MoTN and MoTN-TevT1 vector particles were produced and their titers determined as described previously. 43 The titers of MoTN and MoTN-TevT1 vector particles were approximately 1 × 10 5 colony-forming units per ml, each.
The amphotropic MoTN and MoTN-TevT1 vector particles (500 l) were used to transduce the MT4 44, 45 cell line (2 × 10 6 cells), as described previously. 5, 46 G418-resistant pools of stable MT4 transductants lacking or expressing Tev-RNase T1 were each selected for 3 weeks and used without any cloning.
Human peripheral blood mononuclear cells were isolated from fresh heparinized blood samples from healthy donors by Ficoll-Hypaque gradient centrifugation. Cells were washed once with phosphate-buffered saline (PBS) and cultured at a density of 1 × 10 6 cells/ml in RPMI 1640 containing 10% fetal bovine serum, 20 units/ml of human recombinant interleukin (IL)-2 (Boehringer Mannheim, Mannheim, Germany), and 5 g/ml of phytohemagglutinin (Sigma, St Louis, MO, USA) for a day at 37°C. The suspension cells were collected and cultured for 2 more days. Over 85% of these cells represented T lymphocytes as determined by flow cytometry analysis using T cellspecific monoclonal antibodies. PBLs (1 × 10 6 cells) were then mixed with 1 ml of amphotropic MoTN and MoTNTevT1 vector particles (with 16 g/ml polybrene and 20 units/ml IL-2) and centrifuged at 200 g for 1 h at 32°C and then cultured for 16 h at 32°C. Cells were then incubated for 6 h at 37°C in the presence of IL-2-supplemented medium. The transduction procedure was carried out for a total of three times. Twenty-four hours after the third transduction, cells were cultured for 4 days in IL-2 supplemented medium containing G418 (500 g/ml) and for another 5 days without selection. Cells were checked periodically for growth and viability. RT-PCR analysis of total cellular RNA from stable MT4 transductants was then performed as described previously. 48 The TevT1-5′ and TevT1-3′ primer pair was used to amplify a 943 bp product specific for Tev-RNase T1 RNA. The GAPDH-5′ (5′-CCA-CCC-ATG-GCA-AAT-TCC-ATG-GCA-3′) and GAPDH-3′ (5′-TCT-AGA-CGG-CAG-GTC-AGG-TCC-ACC-3′) primer pair was used as a control to detect the 600 bp product specific for cellular glyceraldehyde-3-phosphate dehydrogenase (GAPDH) RNA. RT-PCR products were analyzed by 2% agarose gel electrophoresis. RT-PCR analysis of total cellular RNA from PBL transductants was performed in a similar manner except that RNA extracted on day 12 after HIV-1 infection was analyzed using the following primers. A 3′ primer (PPT-3′, 5′-AAC-AGA-AGC-GAG-AAG-CG-3′), designed specifically to recognize vector sequences within the Tev-RNase T1 RNA, was used during reverse transcription. The cDNA was then PCR-amplified using T-5′ (5′-GTG-TTG-CTT-TCA-TTG-CC-3′) and R-3′ (5′-CCA-GAA-GTT-CCA-CAA-TC-3′) primers to detect a 331 nucleotide region within the Tev-RNase T1 RNA.
MoTN and MoTN-TevT1 transduced MT4 cells (1 × 10 6 cells) were also analyzed for Tev-RNase T1 protein production. Cells were washed three times with PBS and then lysed for 45 min on ice in a buffer (400 l) containing phenylmethylsulfonyl fluoride (100 g/ml; Sigma), aprotinin (1 mg/ml; Boehringer Mannheim), and Triton X-100 (1%). Cell lysates were centrifuged for 10 min at 10 000 g. Supernatants were collected and Tev-RNase T1 activity was detected by an in situ RNase activity assay as fol-lows. Samples were subject to electrophoresis on a 0.1% SDS-12% polyacrylamide gel embedded with denatured turnip yellow mosaic virus RNA (100 g/ml) as described previously, 36 except that no DTT was included in the loading buffer. Prestained high molecular weight protein standards (GIBCO, Burlington, Canada) were analyzed in parallel. Following electrophoresis, the gel was rinsed four to five times with water and shaken gently at room temperature for 1 h in 300 ml of buffer containing 50 mm Tris-Cl (pH 7.4) and 2 mm EDTA (pH 8.0) to remove SDS and allow protein renaturation. This buffer was replaced and the incubation continued overnight at 37°C to allow Tev-RNase T1 mediated cleavage of RNA. The gel was then stained with ethidium bromide (1 g/ml) and the zone of clearance due to RNase activity was viewed under UV light.
Growth curves of stable MT4 transductants lacking or expressing Tev-RNase T1 Cells were cultured for over 6 months without any signs of toxicity. The growth curves of stable MT4 transductants were determined by performing a viable cell count (by trypan blue exclusion) over a 10-day period.
HIV-1 susceptibility of MT4 and PBL transductants expressing Tev-RNase T1 The pools of actively dividing stable MT4 transductants lacking or expressing Tev-RNase T1 protein (2 × 10 6 cells) were each infected with the HIV-1 strain NL4-3.
49 Cells were infected as described previously 5, 46 using either 30 ng (p24 equivalent) of HIV-1 for 2 h or 100 ng (p24 equivalent) of HIV-1 for 6 h. Transduced PBLs (5 × 10 6 cells) were infected with 1.5 ng (p24 equivalent) of a clinical isolate of HIV-1 for 16 h at 37°C. This isolate was obtained from a pediatric patient infected with HIV-1. Cells were then washed twice with RPMI 1640 medium, resuspended in 750 l of the same medium containing 20 units/ml IL-2 and incubated at 37°C. The culture supernatants were collected every 3 days and replaced with fresh medium. The amount of HIV-1 p24 antigen released in the cell culture supernatant was measured by enzyme linked immunosorbent assay (ELISA; Abbott, Chicago, IL, USA).
HIV-1-infected cells were also tested for the presence of HIV-1 DNA and RNA. Genomic DNA and total cellular RNA were extracted from HIV-1-infected MT4 and PBL transductants lacking or expressing Tev-RNase T1. The DNA and RNA were analyzed by PCR and RT-PCR, respectively, as described previously. 48 DNA and RNA samples from MT4 transductants challenged with HIV-1 (100 ng p24 equivalent) were analyzed on day 3 and day 6 after infection using a 5′ primer within the HIV-1 vpr coding region (Vpr-5′; 5′-ATA-CTT-GGG-CAG-GAG-TGG-AAG-C-3′) and a 3′ primer within the HIV-1 vpu coding region (Vpu-3′; 5′-CTA-TGG-ACC-ACA-CAA-CTA-TTG-C-3′). This primer pair was designed to amplify a 424 bp region within HIV-1 genomic DNA and unspliced and singly spliced HIV-1 RNA. Analysis of DNA and RNA samples from PBL transductants was performed on day 3 after HIV-1 infection using the Gag-5′ (5′-ATA-TCA-TAT-GTA-ATA-CGA-CTC-ATA-TAG-GGC-GAG-AGG-AAG-CTG-CAG-AAT-GGG-A-3′) and the Gag-3′ (5′-GCC-GCC-GAG-ATC-TAC-TAG-3′) primers. This primer pair was designed to amplify a 460 bp gag coding region within HIV-1 provirus DNA and unspliced HIV-1 RNA. The DNA from transduced PBLs on day 3 after HIV-1 infection was also analyzed under semiquantitative PCR conditions. The Gag-5′ and Gag-3′ primers were used to amplify the 460 bp gag coding region within HIV-1 provirus DNA, and Gap-5′ (5′-TCT-ACT-GGC-GCT-GCC-AAG-3′) and Gap-3′ (5′-TCT-AGA-CGG-CAG-GTC-AGG-3′) primers were used to amplify a 122 bp region within the cellular GAPDH DNA and RNA. PCR was performed as described previously, except that the following modifications were made to ensure that a linear relationship exists between the input DNA concentration and the intensity of the PCR products. The 3′ primers were 5′-end labeled as described previously 16 using ␥ 3 × 10 6 c.p.m./g) 3′ primers was increased to 5 g/ml. After 25 cycles of PCR, an aliquot was analyzed by 2% agarose gel electrophoresis followed by exposure to a phosphor screen and scanning by Storm phosphorimager (Molecular Dynamics, Sunnyvale, CA, USA). To ensure that these conditions allow semi-quantitative amplification, Gap-5′ and Gap-3′ primers were used to PCR amplify 1, 10 and 100 g/ml of cellular genomic DNA, and Gag-5′ and Gag-3′ primers were used to PCR amplify 10 to 500 000 copies of HIV-1 pNL4-3 plasmid.
